A real-world analysis on pembro monotherapy versus pembro + chemotherapy for never-smoking NSCLC VJOncology 1:25 2 years ago 82 Скачать Далее
Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC VJOncology 2:12 2 years ago 425 Скачать Далее
Chemotherapy-free immunotherapy-based treatment approaches for NSCLC VJOncology 0:48 2 years ago 141 Скачать Далее
Treating PD-L1-positive NSCLC with immunotherapy alone vs chemoimmunotherapy VJOncology 4:37 1 year ago 665 Скачать Далее
Subgroup analysis of PEARLS/KEYNOTE-091: PD-L1 expression and outcomes of pembrolizumab VJOncology 3:18 1 year ago 639 Скачать Далее
Outcomes of first-line pembrolizumab monotherapy for PD-L1–positive metastatic NSCLC Video Journal of Biomedicine 7:31 2 years ago 1 277 Скачать Далее
Pembrolizumab monotherapy for NSCLC: KEYNOTE-024 update VJOncology 1:02 6 years ago 253 Скачать Далее
KEYNOTE-024 update: pembrolizumab vs platinum-based chemotherapy in NSCLC VJOncology 3:04 3 years ago 492 Скачать Далее
Patients with High PD-L1: Immunotherapy Alone or Combine with Chemo? - ASCO Lung Review 2022 GRACE - Global Resource for Advancing Cancer Education 12:55 2 years ago 295 Скачать Далее
Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agents HMP Education 25:26 6 years ago 1 240 Скачать Далее
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit... ecancer 3:13 5 years ago 494 Скачать Далее
When to consider or NOT consider EV Combination #oncology #lungcancer #cancer #2023 OncBrothers: Practice-Changing Cancer Discussions 0:58 1 year ago 110 Скачать Далее
Pembro continues to demonstrate OS benefit in first-line NSCLC: KEYNOTE-024 update VJOncology 1:20 5 years ago 124 Скачать Далее
KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy VJOncology 1:14 6 years ago 153 Скачать Далее
KEYNOTE-407: pembrolizumab plus chemo improves OS and PFS in NSCLC VJOncology 2:53 3 years ago 392 Скачать Далее